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ABSTRACT 
 Antimicrobial treatment regimens are generally based on pharmacokinetic data 
established in healthy animals. Likewise, in food animals, antimicrobial withdrawal times are 
based on pharmacokinetic data from healthy animals. In clinical practice, antimicrobials are 
therapeutically used in disease challenged animals. There is limited literature addressing the 
question of pharmacokinetic changes in diseased animals. Considering swine, there are 
approximately 17 searchable peer reviewed studies addressing disease influence on 
antimicrobial pharmacokinetics. Across those studies there are about 28 disease-
antimicrobial interactions evaluated, of which 21 find that disease changes the 
pharmacokinetics of the evaluated antimicrobial. None of the current studies address the 
influence vaccination may have on preserving antibiotic pharmacokinetics in the face of 
disease challenge. 
Original research was performed to evaluate the pharmacokinetics of ceftiofur 
crystalline free acid in pigs vaccinated against, challenged with, or vaccinated against and 
challenged with PRRSv. The original research hypothesized that PRRSv wild-type challenge 
would change pharmacokinetics and previous vaccination would have no effect on 
pharmacokinetic variables. Previous research had shown ceftiofur pharmacokinetics change 
with PRRSv infection. The PRRSv vaccine investigated is a commonly used and 
commercially available modified live virus. The present work found that a wild-type PRRSv 
infection resulted in a lower AUC0-last, higher Cl/F and higher Vz/F. The present work also 
determined that the modified live virus used for vaccination did not result in any 
pharmacokinetic changes, and vaccination with the modified live virus prevented 
pharmacokinetic changes in pigs that were subsequently challenged with a wild-type virus. 
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Disease or infection of a virulent organism does not always change antimicrobial 
pharmacokinetics. Pharmacokinetic changes seem dependent on specific antimicrobial and 
specific organism. Available research demonstrates PRRSv infection does change 
pharmacokinetics of ceftiofur drugs. Original research reported in this thesis suggests a 
modified live PRRSv vaccination has the potential to prevent ceftiofur pharmacokinetic 
changes that occur in the face of a wild-type PRRSv challenges. This information may be 
clinically applied by following labeled pharmacokinetic parameters of ceftiofur crystalline 
free acid in pigs vaccinated with a modified live PRRSv, regardless of wild-type PRRSv 
challenge.
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CHAPTER 1 
 GENERAL INTRODUCTION 
 
Thesis introduction 
 Antimicrobial dosing regimens are based on pharmacokinetic (PK) data. PK data is 
typically derived from healthy animals. Veterinarians often follow suggested dosing regimens 
when therapeutically treating diseased animals. In swine, there is a moderate amount of research 
observing certain antimicrobial PK changes in diseased animals. The PK changes observed in 
diseased animals have potential to change antimicrobial efficacy and ultimately clinical outcome. 
Considering food animals, alterations in pharmacokinetics can also have influence on withdrawal 
times. 
 There are two studies specifically investigating how PRRSv infection changes 
antimicrobial PK. Both studies evaluate the PK of ceftiofur hydrochloride. One study used solely 
a PRRSv challenge model (Tantituvanont et al., 2008), and the other study used a PRRSv and 
Streptococcus suis co-challenge model (Day et al., 2015). Both studies observed ceftiofur PK 
changes where disease challenged resulted in decreased Cmax, decreased AUC, increased Cl/F, 
and increased Vz/F. This previous research instigated questions about the influence of PRRSv on 
longer acting ceftiofur preparations and the role PRRSv vaccination might have on disease 
altered PK parameters. The goal of this thesis was to understand the pharmacokinetics of 
ceftiofur crystalline free acid in pigs vaccinated against, challenged with, or vaccinated against 
and challenged with PRRSv. 
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Thesis organization 
 This thesis consists of five chapters. Chapter 1 is thesis introduction, organization, and 
objectives. Chapter 2 is a brief introduction to existing PK research that focuses on diseased 
swine. Chapter 2 focuses on proposed or defined mechanisms that support observed PK changes 
that exist in animals. Chapter 3 is titled “Vaccination mitigates the impact PRRSv infection has 
on the pharmacokinetics of ceftiofur crystalline free acid in pigs,” and will be submitted to the 
Journal of Veterinary Pharmacology and Therapeutics for publication. Chapter 4 includes 
additional methods and results from the original research explained in Chapter 3. Chapter 5 is a 
summary and conclusion with brief review on possible PRRSv interactions that may contribute 
to observed PK changes. 
Thesis objectives 
The objectives of Chapter 2 were, 1) to offer an updated summary to a previously 
completed literature review focusing on antimicrobial PK changes in swine, and 2) Review 
current literature to summarize possible mechanisms responsible for disease changing 
antimicrobial pharmacokinetics. The objectives of Chapter 3 were defined as part of the original 
research study as being 1) determine if PRRS MLV alone impacts the pharmacokinetic profile of 
ceftiofur crystalline free acid in pigs, 2) determine if PRRS MLV vaccination prevents PK 
impacts when vaccinated pigs are challenged with a wild-type PRRSv. The objective of Chapter 
4 was to include and explain additional methods and results of Chapter 3; though the information 
was important to the original research, it was truncated from Chapter 3 for publication purposes. 
The objective of Chapter 5 was to identify possible mechanisms specifically related to PRRSv 
that may contribute to observed antimicrobial PK changes. Chapter 5 also serves as a final 
conclusion for the thesis. 
3 
 
 
CHAPTER 2 
 ANTIMICROBIAL PHARMACOKINETICS IN DISEASED SWINE AND PROPOSED 
MECHANISMS FOR OBSERVED CHANGES 
 
Introduction 
Considering swine, there are approximately 17 peer reviewed searchable studies 
addressing disease influence on antimicrobial pharmacokinetics. Across those studies there are 
about 28 disease-antimicrobial interactions evaluated. Among the 28 interactions, 21 find that 
disease changes the pharmacokinetics of the evaluated antimicrobial. Table 1 is adapted, 
updated, and modified from Day (2014), and it summarizes the studies among swine that 
evaluate disease influence on antimicrobial pharmacokinetics. Each study shares a common 
objective of determining the pharmacokinetic influence disease might have on a given 
antimicrobial administered to swine. Ultimately, it is difficult to recognize a common theme for 
disease influence on antimicrobial pharmacokinetics. Yet, each study has a unique disease-
antimicrobial interaction. 
The available research spans 36 years (Ladefoged, 1979 to Day et al., 2015) and several 
research groups. When evaluating these studies it is important to be cognizant of differences. The 
following is a brief list of points of variability that exists in study design: breed and sex of pigs, 
methods of disease introduction, virulence of organism used, use of actual organism or products 
produced by organism, timing of disease inoculation prior to pharmacokinetic assessment, 
verification of disease state, blood collection, number and duration of blood collections for PK 
analysis, methods of drug extraction and quantification, pharmacokinetic modeling and 
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programs, pharmacokinetic parameters reported, statistical analysis and programs.  Beyond 
characteristics of explicit study design, there are points of variation that are not mentioned, 
which could include the following: conditions of the animals housing, daily care of the animals, 
methods for handling and restraining the animals, and laboratory protocols for handling samples. 
The listed areas of variation are not complete but rather suggest points where differences can 
change interpretable results. These areas of variation make it difficult for general applications 
and interpretations. However, if studies are individually evaluated in context of all available 
information, clinical interpretations and applications may still be made. 
Within each journal article evaluating disease influence on antimicrobial 
pharmacokinetics, authors offer explanations as to why pharmacokinetic changes are or are not 
observed. Some explanations are derived from original research conducted within the given 
study. Some explanations reference previously published articles. Some explanations are 
speculation based on known physiological mechanisms. The remainder of this thesis chapter will 
review some of the explanations and theories other authors have offered for the mechanisms of 
altered pharmacokinetics in a disease state. 
Renal function 
 Kidneys serve as a major excretory route from many drugs.  Renal drug excretion may 
occur through glomerular filtration, tubular secretion, or passive diffusion (Riviere, 2009a). 
Renal reabsorption may also occur, transporting drugs back into the vasculature. Plasma 
clearance is the most probable PK parameter to show changes with altered renal function. 
Mengelers et al. (1995) measured urine volume, pH, and drug content in pigs challenged 
with APP toxin and administered sulfadimethoxine/trimethoprim or 
sulfamethoxazole/trimethoprim. Disease challenge increased plasma drug clearance of 
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trimethoprim in both combinations, but there were no clearance changes of sulfadimethoxine or 
sulfonamide. In both drug combinations, amount of trimethoprim excreted in urine was higher in 
APP toxin challenged pigs. Amounts of sulfadimethoxine, sulfamethoxazole, and metabolites 
excreted in urine did not differ between challenge and control pigs. Urine volume and pH 
showed no difference between any treatment groups. The authors could not offer an explanation 
for the observed increase of trimethoprim clearance in APP toxin challenged pigs. However, they 
did conclude that urine pH and volume did not contribute to the observed clearance changes. 
Post et al. measured urine content of enrofloxacin and ciprofloxacin when studying 
enrofloxacin PK in pigs challenged with APP (Post el al., 2002) or E. coli LPS (Post et al., 
2003). APP challenge resulted in no change of plasma drug clearance. E. coli LPS challenge 
resulted in decreased plasma drug clearance. Dexamethasone, chosen for anti-inflammatory 
properties, was included in both studies as an effect of a 2x2 factorial design. In both studies, 
enrofloxacin/creatinine ratio and ciprofloxacin/creatinine ratio were used to estimate drug 
clearance by renal excretion. Creatinine normalization was utilized to avoid confounding that 
may occur from increased drinking and urination resultant of dexamethasone usage. APP 
infection did result in a lower enrofloxacin/creatinine and ciprofloxacin/creatinine ratios at 24 
hours but not at 48hrs. Reference is made indicating APP does not change hepatic metabolism or 
renal blood flow, as evidenced by indole cyanine green and creatinine clearance (Monshouwer et 
al., 1995). Post et al. concluded APP may inhibit renal tubular secretion or enhance reabsorption. 
However, the authors acknowledge that this observation may only be transient. Considering E. 
coli LPS challenged pigs, total enrofloxacin equivalents in urine was greater 48 to 72 hours after 
drug administration. This increase was not observed in the E. coli LPS challenged pigs also 
receiving dexamethasone, which led authors to suggest that the increased renal excretion of drug 
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was likely a result of inflammation. However, the total urine equivalents for the entire study did 
not differ from control animals.  These observations were explained to be a result of decreased 
plasma clearance in LPS challenged pigs.  
Considering pharmacokinetics in disease challenged swine, other studies addressing renal 
function do not have original research but have references and suggestions. Zeng and Fung 
(1990) observed increased clearance of penicillin G in Streptococcus suis challenged pigs. They 
suggested increased clearance could be a result of fever and consequent increased renal blood 
flow, which was shown in previous literature (van Miert, 1985).  
Jensen et al. (2006) studied oral amoxicillin pharmacokinetics in E.coli challenged pigs, 
and found, relative to control pigs, disease decreased then increased clearance on day one and 
day two after amoxicillin administration, respectively. They suggested E. coli diarrhea could 
have changed hydration status possibly resulting in renal dysfunction changes between day one 
and two. Dehydration was not clinically noted. They also referenced a study demonstrating E. 
coli endotoxin being able to decrease renal clearance in dogs (Marier et al., 2001).  
Yuan et al. (1997) completed a study showing an increased ampicillin clearance but a 
decreased sulfadimidine clearance in Streptococcus suum challenged pigs. With knowledge of 
ampicillin being eliminated by active tubular secretion, they suggest Streptococcus suum 
infection increases renal tubular secretion, resulting in greater ampicillin clearance. They 
attributed decreased sulfadimidine clearance to decreased glomerular filtration, which is 
presumed to be decreased in Streptococcus suum infection. 
Considering the importance of renal function, there is little research addressing renal 
changes and influences on pharmacokinetics in diseased swine. From available research 
(Mengelers et al. 1995; Post et al. 2002; Post et al. 2003), kidneys of disease challenged swine 
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appear to maintain functional capacity with none to minor changes in antimicrobial 
pharmacokinetics. However this concept has high potential to be disease and drug specific. 
Plasma Protein binding 
 Clinical pharmacokinetics, especially those used among swine, are based upon drug 
concentrations in the vasculature. With studies pertaining to swine there are three general routes 
a drug will enter the vasculature 1) direct intravenous injection, 2) absorption from an 
intramuscular or subcutaneous injection site, or 3) absorption from the gastrointestinal tract. 
Once in the vasculature, many classes of drugs are subject to some degree of protein binding. 
Albumin is often considered a highly important protein for drug protein binding to facilitate 
distribution. Covalent, noncovalent, and ionic binding are examples of common interactions a 
drug might have with a plasma protein. If a drug is bound to a plasma protein it is generally not 
considered available for distribution or excretion. It is the non-bound drug that is available for 
distribution into tissues or excretory elimination from the body (Riviere, 2009a). Change in 
plasma proteins is one theory for observed pharmacokinetic changes in disease pigs.  
 Mengelers et al. (1995) measured protein binding by ultrafiltration, when evaluating 
sulfadimethoxine/trimethoprim or sulfamethoxazole/trimethoprim in APP toxin challenged pigs. 
For all treatment groups, proportion of protein binding in the vasculature for sulfadimethoxine, 
sulfamethoxazole, and trimethoprim was 94-99%, 45-56%, and 40-50%, respectively. Protein 
binding of all drugs and metabolites was consistently lower in the disease challenged pigs, but 
the difference was not statistically significant.  
 Lindercrona et al. (2000) studied danofloxacin pharmacokinetics in pigs challenged with 
Salmonella typhimurium. They found that challenged pigs had a significantly higher percent of 
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protein binding, 53±8% versus 44±8% in control animals. The authors offered no explanation for 
the higher protein binding in disease challenged animals. 
 Agerso et al. (1998) studied amoxicillin pharmacokinetics in APP challenged pigs. 
Amoxicillin protein binding in plasma and bronchial secretions was measured by ultrafiltration. 
The results were not compared to control animals. They found amoxicillin protein binding to be 
17±8% in plasma and 13±6% in bronchial secretions. They also concluded that similar 
concentrations of amoxicillin in pleural fluid and plasma indicate the protein binding in pleura 
fluid is similar to the protein binding of plasma. 
 Tantituvanont et al. (2009) observed increased volume of distribution and clearance in 
PRRSv infected pigs. They did not directly measure protein binding or plasma proteins. 
However, they did reference the possible decline in plasma albumin with pneumonia (Parra et 
al., 2006), which would leave more non-protein bound drug available for distribution or 
excretion. Others have simply alluded to the concept of protein binding. Zeng and Fung (1990) 
suggest lower plasma protein binding could be the cause of their observed increased volume of 
distribution for penicillin G in S. suis challenged pigs. Yuan et al. (1997) suggests decreased 
plasma proteins may be an explanation to their observed increase in volume of distribution and 
clearance of Ampicillin in Strep suum infected pigs. 
Vascular permeability, flow, and pH 
 As previously mentioned, the vasculature is commonly considered the central 
compartment for pharmacokinetics. Reasonably, changes of the vasculature would be expected 
to change absorption, distribution, metabolism, or excretion for a given drug. There are several 
plausible physiological explanations of how disease may change vasculature to influence 
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pharmacokinetics. However, there is little original research measuring these changes directly in 
swine. 
 Agerso et al. (1998) studied pharmacokinetics and tissue distribution of IV amoxicillin in 
APP challenged pigs. There was an increased volume of distribution of infected animals 
compared to the controls. They concluded this increased volume of distribution was a result of 
change in peripheral compartments and suggested a possible cause being dilated capillaries with 
increased vascular supply to the infected region. The authors also reference the idea that 
infection induced fever and subsequent shivering could divert blood flow and alter 
pharmacokinetics (Blatteis et al., 1988).  Agerso et al. (2000) also studied pharmacokinetics and 
tissue distribution of IM amoxicillin in Salmonella typhimurium challenged pigs. In this case 
amoxicillin tissue distribution of infected animals was numerically, not statistically, decreased. 
There was a statistically significant increase of mean residence time and volume of distribution 
in infected animals. They suggested dilated capillaries and altered blood flow as possible, but not 
ultimate, causes. 
 The concept of changes in blood pH has been another suggestion of how disease may 
change antimicrobial pharmacokinetics. Drug ionization is usually dependent on pH, and 
ionization influences the ability for a compound to cross biological membranes (Riviere, 2009a). 
Mengelers et al. (1995) measured urine pH when studying sulfadimethoxine/trimethoprim or 
sulfamethoxazole/trimethoprim in APP toxin challenged pigs. Urine pH has some potential to 
offer inference of blood pH. They did not find any difference between control and challenged 
pigs. Others have suggested the concept of pharmacokinetic changes being resultant of disease 
influenced vasculature pH, but there is no original research or referencing (Zeng and Fung, 1990; 
Agerso et al., 1998; Day, 2014).  
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Gastrointestinal absorption 
Orally administered drugs are open to a unique area of influence. Disease impact on 
gastrointestinal function has changes mostly manifested in drug absorption. When considering 
the influence disease has on orally administered antimicrobial pharmacokinetics, it is important 
to recognize areas of variability. In experimental conditions the drug may be provided ad libitum 
in feed, ad libitum in water, placed in the oral cavity, or gavaged. In some studies, animals are 
fasted prior to drug administration.  
Pijpers et al. (1991) evaluated oxytetracycline in fasted pigs challenged with APP toxin. 
They found disease resulted in increased AUC and Vd, while decreasing Cmax and Cl. A 
suggested cause was delayed gastric emptying allowing more time for drug absorption. They 
referenced work in rats that demonstrated disease may delay gastric emptying and changed 
gastric pH (Leenen and van Miert, 1969; van Miert AS, De la Parra DA, 1970). However, they 
also acknowledged other aspects of disease can contribute to changes in drug absorption, 
referencing fever in calves changing absorption for an intramuscularly administered drug 
(Groothuis et al., 1980).  
Jensen et al. studied E. coli challenged pigs administered amoxicillin by oral gavage 
(2004) and ad libitum in drinking water (2006). E. coli challenged pigs administered amoxicillin 
by oral gavage had a lower AUC and Cmax, relative to control pigs. Studies in rats and people 
have demonstrated amoxicillin absorption occurs through a sodium exchange mechanism and 
passive diffusion (Westphal et al., 1995; Sugawara et al., 1990). E.coli diarrhea is due to a 
secretory sodium-chloride mechanism (Argenzio, 1984) and, to a lesser extent, loss of intestinal 
surface area (Vijtiuk et al., 1995). Using the aforementioned references, Jenson et al. (2004) 
suggested their observed pharmacokinetic changes are a result of amoxicillin absorption and E. 
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coli secretion competing for the same mechanism along with a general reduction of intestinal 
absorptive surface area. In the later study by Jensen et al. (2006), relative to control pigs, E. coli 
challenged pigs with ad libitum access to amoxicillin treated water had decreased AUC, 
decreased Cmax, and deceased Kel one day after amoxicillin access, but conversely two days after 
amoxicillin access, AUC, Cmax, and Kel were significantly increased relative to control. They 
again suggested a competitive mechanism and reduced intestinal surface area for day one PK 
changes. The shift seen from day one to two was assumed to be a result of partially saturating the 
absorptive capacity for amoxicillin by use of a large dose. 
Godoy et al. (2011) studied pharmacokinetics of amoxicillin administered by ad libitum 
feed in pigs naturally infected with PRRSv.  The study observed higher AUC and Cmax in disease 
challenged pigs, when compared with non-diseased pigs. They suggested that a reduction in 
intestinal transit rate increased the amount of time the amoxicillin medicated feed was residing in 
the intestinal tract, allowing for more absorption. A rat study was sited to reference ampicillin 
bioavailability doubled with increasing time the drug set in the small intestine (Haruta et al., 
1998). The authors also briefly mentioned blood flow, hepatic function, renal function, and 
hydration are potential causes for pharmacokinetic changes in diseased animals.  
In addition to the physiologic drug-body interaction, animal behavior in a disease state 
may be a key point of influence. Sick animals may be lethargic and not be as ambitious to drink 
or eat. Pijpers et al. (1991) measured water and feed consumption and observed significant 
decreases in diseased pigs. Godoy et al. (2011) noted animal behavior is highly variable on the 
individual level and animal behavior in a disease state can decrease consumption of medicated 
ad libitum feed or water. 
12 
 
Medicated feed and water are common routes of antimicrobial therapy in commercial 
swine (Food and Drug Administration, 2013). As seen with other routes of medication, disease 
has potential to change orally administered pharmacokinetics in diseased swine. Functionality of 
the gastrointestinal tract is an added consideration when giving oral antimicrobials. Intestinal 
motility, altered pH, and possible interference with antimicrobial transmembrane transport are 
major areas discussed by the authors that studied oral antimicrobial pharmacokinetics in diseased 
pigs.  Though not directly considered a pharmacokinetic parameter, disease induced lethargic 
behavior has the potential to be a significant factor in the ability of an ad libitum oral 
antimicrobial to make it to the target site in a diseased pig. 
Other possible mechanisms changing pharmacokinetics in diseased swine 
  Considering swine literature, the preceding paragraphs include more prevalent ideas 
regarding mechanisms for antimicrobial pharmacokinetic changes seen in diseased challenged 
swine. However, there are a few other mechanistic suggestions. Considering inflammatory 
mediators, Post et al. (2002) measured IL-6 in APP challenge pigs given enrofloxacin. They 
found IL-6 elevated in challenged pigs, but there was no conclusion made from the observation. 
Lindercrona et al. (2000) suggested alteration in hepatic metabolism as a possible change for 
danofloxacin pharmacokinetics in Salmonella typhimurium challenges pigs. Lui et al., (2003) 
noticed no difference in florfenicol pharmacokinetics when given IV, IM, or orally to APP 
challenged pigs. They suggested the reason for no observed change stems from APP causing 
respiratory disease and not having much effect on liver or kidneys. 
Summary on mechanisms changing pharmacokinetics in disease swine 
There are numerous ways to dissect and categorize the possible mechanisms related to 
antimicrobial pharmacokinetic changes seen in diseased pigs. The best deduction is that disease 
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or infection has potential to change antimicrobial pharmacokinetics in a manner specific to the 
particular drug and disease combination. Given the present research in swine, a consistent 
generalized conclusion cannot be made. However, studies evaluating disease influence on 
antimicrobial pharmacokinetics in swine can be descriptively represented (Table 1). It is 
important to realize specific drug of interest and specific disease of interest is relevant. Within 
the pharmacokinetic studies, there is little original research attempting to explain mechanisms 
behind observed pharmacokinetic changes. In clinical settings, it is best to take original research, 
correlated with the conditions, and make the best decision for the specific circumstances. 
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CHAPTER 3 
 VACCINATION MITIGATES THE IMPACT PRRSV INFECTION HAS ON THE 
PHARMACOKINETICS OF CEFTIOFUR CRYSTALLINE FREE ACID IN PIGS 
 
 
To be submitted to Journal of Veterinary Pharmacology and Therapeutics for publication. 
 
J.W. Sparks, L.A. Karriker, D.N. Day, L.W. Wulf, J.Q. Zhang, D.M. Madson, M.L. Stock, J.L. 
Bates, R. Gehring, J.F. Coetzee
 
 
Abstract 
The pharmacokinetics of intramuscularly administered ceftiofur crystalline free acid 
(CCFA) were determined in pigs that were clinically healthy, vaccinated with a PRRS MLV, 
challenged with wild-type PRRSv VR-2385, or vaccinated with PRRS MLV and later challenged 
with wild-type PRRSv VR-2385. Animals were given a single dose intramuscularly at 5mg/kg 
bodyweight. Blood was collected at 0 (pre-treatment), 0.25, 0.5, 1, 6, 12, 24, 48, 96, 144, 192, 
and 240 hours post injection.  Plasma was analyzed using liquid chromatography-mass 
spectrometry. Plasma concentration-time curves for each group were evaluated with 
noncompartmental modeling. Vaccination and challenge models were confirmed with strain 
specific RT-PCRs performed on lung or tonsil tissue. When compared to control animals, those 
receiving the PRRSv wild-type challenge had a lower AUC0-last, higher Cl/F, and higher Vz/F. 
Control animals had no statistically significant differences from animals vaccinated with PRRS 
MLV alone or animals vaccinated with PRRS MLV and later challenged with wild-type PRRSv. 
Vaccination with PRRS MLV does not change the pharmacokinetics of CCFA, and our results 
suggest that when faced with wild-type PRRSv challenge, vaccination with PRRS MLV 
preserves pharmacokinetics of CCFA.  
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Introduction 
Treatment regimens are generally based on pharmacokinetic (PK) profiles established in 
healthy animals. In clinical practice, antibiotics are therapeutically used in disease challenged 
animals. There is limited literature addressing the question of PK profile changes in diseased 
animals. Tantituvanont et al. (2008) studied pharmacokinetics of intramuscular injections of 
ceftiofur hydrochloride and found pigs intranasally challenged with porcine reproductive and 
respiratory syndrome virus (PRRSv) had decreased area under the curve (AUC), maximum 
plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and terminal 
elimination half-life (T1/2z), while there was an increased clearance per fraction dose absorbed 
(Cl/F) and volume of distribution per fraction dose absorbed (Vz/F).  
PRRSv has been estimated to annually cost the U.S. swine industry $664 million 
(Holtkamp et al., 2013). PRRSv is known for interstitial pneumonia and reproductive failure 
(Rossow, 1998). PRRSv is also capable of causing increased susceptibility to secondary bacterial 
infections (Brockmeier et al., 2001; Thacker et al., 1999; Thanawongnuwech, et al., 2000).  
Ingelvac® porcine reproductive and respiratory syndrome modified live virus (PRRS 
MLV) is an attenuated PRRSv strain. PRRS MLV is marketed and labeled to aid in disease 
reduction for both reproductive and respiratory forms of PRRSv. Vaccination with a PRRS MLV 
has been noted to reduce viremia, fever, and lung lesions when challenged with a virulent 
PRRSv (Johnson et al., 2004 and Nodelijk et al., 2001). 
Ceftiofur crystalline free acid (CCFA) is a third generation cephalosporin.With swine, a 
majority of CCFA is metabolized to desfuroylceftiofur. CCFA, desfuroylceftiofur, and any 
metabolites possesing the β-lactam ring may be active against bacterial cell wall synthesis 
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(Beconi-Barker, 1995). CCFA for treatment of swine respiratory disease has proven efficacy 
against gram-postive and gram-negative bacteria, including β-lactamase  producing strains (Food 
and Drug Administration, 2010).  According to current labels, CCFA  is a longer acting ceftiofur 
preparation when compared to ceftiofur hydrochloride, and ceftiofur sodium, with half-lives of 
49.6, and  16.2, and 14.0 hours, respectively. 
The objectives of this study were 1) determine if PRRS MLV alone impacts the 
pharmacokinetic profile of ceftiofur crystalline free acid in pigs, 2) determine if PRRS MLV 
vaccination prevents PK impacts when vaccinated pigs are challenged with a wild-type PRRSv. 
Materials and methods 
Animals and housing 
Thirty-eight clinically healthy and PRRSv naïve crossbred barrows were sourced from a 
commercial herd. They were 3 to 4 weeks of age and weighed an averaged 9.8 kg at time of 
allotment.  Each treatment group was housed in a separate biosecure and climate controlled room 
at Iowa State University Livestock Infectious Disease Isolation Facility. All rooms contained a 
single pen measuring 13.4m2 on a solid concrete floor. Pigs were allowed ad libitum access to a 
corn-soybean meal based diet without added antimicrobials. Pigs were allowed ad libitum access 
to water without antimicrobials by two nipple drinkers. All live animal care and procedures were 
in accordance with a protocol approved by Iowa State University’s Institutional Animal Care and 
Use Committee (4-13-7542-S). 
Experimental Design 
An individual pig was considered the experimental unit. Pigs were blocked by weight and 
randomly allotted to one of four treatment groups. The first group served as control, receiving 
neither PRRS MLV nor PRRSv challenge (Control group, n=8). The second group received only 
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PRRS MLV vaccination five days prior to PK assessment (Vx group, n=10). The third group 
received only PRRSv wild-type challenge five days prior to PK assessment (Challenge group, 
n=10). The fourth group received PRRS MLV vaccination thirty-three days prior to PK 
assessment and received PRRSv wild-type challenge five days prior to PK assessment 
(Vx+Challenge group, n=10).  The PK assessment for each group had a ten day duration. All 
pigs were necropsied at conclusion of the PK assessment. Necropsy was to harvest lung and 
tonsil tissues for diagnostics and viral characterization. A summary of study design is outlined in 
Table 2. 
Veterinary products 
CCFA (EXCEDE® FOR SWINE, Lot number 3F0184, Zoetis, Kalamazoo, MI, USA) 
was used as packaged, with each milliliter containing 100mg of ceftiofur equivalents in a 
Miglyol® and cottonseed oil based suspension. Injections were intramuscular in the post-
auricular region of the right neck. On study day 0, administration of CCFA initiated the start of 
an individual pig’s PK assessment.  
Ingelvac® PRRS MLV (Serial number 245-D45, Boehringer Ingelheim Vetmedica, INC., 
St Joseph, MO, USA) was used as a modified live PRRSv vaccine. The vaccine was handled and 
reconstituted in accordance with labeled instructions. A 2mL PRRS MLV dose was administered 
using a 3mL syringe and 20gauge by1 inch needle (Monojet™ Syringe with Luer-Lock Tip and 
Veterinary Needle, Covidien, Mansfield, MA, USA). Injections were intramuscular in the post-
auricular region of the left neck. 
PRRSv challenge inoculum  
The PRRSv challenge inoculum was prepared as previously reported (Day, 2014). 
Briefly, PRRSv isolate VR-2385 was initially recovered from a sow herd in southwestern Iowa 
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that experienced severe respiratory diseases in 3-16 weeks old pigs and late-term abortions in 
1991 (Halbur et al., 1995). VR-2385 strain has been used for experimental infection or challenge 
in numerous studies (Doeschl-Wilson et al., 2009; Opriessnig et al., 2007; Thanawongnuwech et 
al., 1998). VR-2385 strain was propagated in Marc-145 cells, a clone of the African monkey 
kidney cell line MA-104 (Kim et al., 1993). The cells were cultured and maintained in RPMI-
1640 Medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine 
serum, 2 mM L-Glutamine, 0.05 mg/ml Gentamicin, 10 unit/ml penicillin, 10 µg/ml 
Streptomycin, and 0.25 µg/ml Amphotericin. Virus titration was performed in 96-well plates of 
Marc-145 cells by inoculating 10-fold serial dilutions of the virus (100 µl per well), triplicate per 
dilution. After 5 days inoculation, virus-specific cytopathic effect was recorded and the plates 
were subjected to immunofluorescence staining with PRRSv specific monoclonal antibodies 
conjugated to fluorescein isothiocyanate. The virus titers were determined according to the Reed 
and Muench method (Reed and Muench, 1938) and expressed as 50% tissue culture infective 
dose per milliliter (TCID50/ml). Five days prior to PK assessment, each pig in Challenge and 
Vx+Challenge groups received a 2mL intranasal dose at a concentration of 105.6 TCID50/mL 
using a 3mL syringe (Monojet™ Syringe with Luer-Slip Tip, Covidien, Mansfield, MA, USA). 
Routine diagnostics and viral characterization 
 Prior to enrollment in the study, serum was collected from all pigs for PRRSv standard 
PCR and PRRSv antibody ELISA to confirm naïve status. Serum was collected from the 
Vx+Challenge group immediately prior to challenge, five days prior to PK assessment, for 
PRRSv antibody ELISA to confirm successful vaccine response. Serum was collected from all 
pigs on day 0, immediately prior to starting the PK assessment, for PRRSv standard PCR to 
confirm infection and/or vaccination status. Serum was collected from all pigs on day 9, prior to 
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necropsy, for PRRSv standard PCR to confirm infection and/or vaccination status at the end of 
the study. All serum was submitted to the Iowa State University Diagnostic Laboratory for 
routine testing. All samples for ELISA were tested with HerdChek X3® PRRSv antibody ELISA 
(IDEXX Laboratories, Inc., Westbrook, Maine) with a sample to positive ratio of ≥ 0.4 
considered positive. Samples for PCR collected prior to allotment and on day 0 were tested using 
the Tetra-core PRRSv PCR with a cycle threshold of ≥ 40 considered positive. Samples for PCR 
collected prior to necropsy, on day 9, were tested using the Applied Biosystems PRRSv PCR 
with a cycle threshold of ≥ 37 considered positive. Both PCRs were the routine PRRSv PCRs 
offered to clients of the ISU VDL at the respective sample submission time points. 
 At necropsy, lung and tonsil tissues were collected for characterization of PRRSv viral 
strain. If lung samples were negative for PRRSv, tonsil was tested. Standard PRRSv PCR is 
unable to differentiate between the PRRS MLV and PRRSv VR-2385 viral strains. A reverse 
transcription PCR (RT-PCR) was developed to distinguish the Ingelvac® PRRS MLV from the 
PRRSv VR-2385 wild-type virus. The RT-PCR used virus-specific primers targeting both the 
ORF5 and the nsp2 genomic segments. The Ingelvac® PRRS MLV ORF5 was amplified and 
sequenced using the primers IngelvacMLV(ORF5)_77F and IngelvacMLV(ORF5)_574R with 
the thermal cycler conditions of 50°C 30 min, 95°C 15 min, 40 cycles (94°C 30 sec, 53°C 30 sec, 
72°C 1 min), and 72°C 10 min. The PRRSv VR-2385 ORF5  was amplified and sequenced using 
the primers VR2385(ORF5)_77F and VR2385(ORF5)_574R with the thermal cycler conditions 
of 50°C 30 min, 95°C 15 min, 40 cycles (94°C 30 sec, 56°C 30 sec, 72°C 1 min), and 72°C 10 
min. The Ingelvac® PRRS MLV nsp2 was amplified and sequenced using the primers 
IngelvacMLV_3007F and IngelvacMLV_3944R with the thermal cycler conditions of 50°C 30 
min, 95°C 15 min, 40 cycles (94°C 30 sec, 60°C 30 sec, 72°C 1.5 min), and 72°C 10 min. The 
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PRRSv VR-2385 nsp2 was amplified and sequenced using the primers VR2385_3008F and 
VR2385_3510R with the thermal cycler conditions of 50°C 30 min, 95°C 15 min, 40 cycles 
(94°C 30 sec, 56°C 30 sec, 72°C 1 min), and 72°C 10 min.  
Pharmacokinetic drug administration and blood sampling 
 Individual pigs were re-weighed within 12 hours of commencement of the PK 
assessment. Weights were used to calculate the dose of 5.0mg ceftiofur equivalents per kilogram 
body weight. Doses were rounded to the closest 1/10th of a milliliter. Injections were 
intramuscular in the post-auricular region of the right neck using a 3mL syringe and 20 gauge by 
1 inch needle (Monojet™ Syringe with Luer-Lock Tip and Veterinary Needle, Covidien, 
Mansfield, Massachusetts, USA).  
Blood was sampled 0 (pre-treatment), 0.25, 0.5, 1, 6, 12, 24, 48, 96,144,192, and 240 
hours post-injection. Blood was collected from the jugular furrow using a 12mL syringe and 18 
gauge by 1.5 inch needle (Monojet™ Syringe with Luer-Lock Tip and Veterinary Needle, 
Covidien, Mansfield, MA, USA) while pigs were manually restrained. Blood was immediately 
transferred to a 6.0 mL lithium heparin Vacutainer® (Becton, Dickinson and Company, Franklin 
Lakes, New Jersey, USA), inverted at least five times, and placed in a cooler with ice. Samples 
would remain in a cooler no longer than two hours before being centrifuged at 1000g and 4°C for 
10 minutes. Using disposable transfer pipettes, plasma was transferred to individual cryovials. 
Plasma was stored at -70°C until plasma analysis was performed.  
Plasma analysis 
Plasma concentrations of ceftiofur equivalents were determined using liquid 
chromatography coupled with mass spectrometry (LC-MS). All laboratory personnel conducting 
plasma analysis were blinded to treatment group. The LC-MS system consisted of an Accela 
21 
 
Pump and Autosampler, (Thermo Scientific, San Jose, CA, USA) coupled to an ion trap mass 
spectrometer (LTQ  XL, Thermo Scientific, San Jose, CA, USA). Ceftiofur residues (total 
ceftiofur, ceftiofur equivalents) were determined by cleavage of ceftiofur, its metabolites, and 
protein bound residues to desfuroylceftiofur with dithioerythritol (DTE) followed by 
derivatization with iodoacetamide. The stable derivative, desfuroylceftiofuracetamide (DCA), 
was then analyzed by LC-MS. Deuterated ceftiofur, d3-ceftiofur was used as the internal 
standard which became d3-desfuroylceftiofuracetamide upon cleavage and derivatization. 
Cleanup of the derivatized samples was performed by solid phase extraction (SPE) using Oasis 
HLB cartridges (Waters Associates, Milford, MA, USA). Plasma samples, plasma calibrators, 
and quality control (QC) samples, 200 µL, were treated with 3 mL of 0.5% DTE in borate buffer, 
0.05 N, pH 9.0 after addition of 10 µL of a 10 ng/µL solution of the internal standard, d3-
ceftiofur. The samples were vortexed for 5 seconds and placed in a 50°C water bath for 15 
minutes. Upon removal from the water bath and cooling to room temperature, 0.5 mL of 14% 
iodoacetamide in phosphate buffer (0.025 M, pH 7) was added followed by the samples being 
left in the dark for 30 minutes. Following derivatization, the samples were cleaned up on an 
Oasis HLB SPE column (60 mg/3 mL) that was preconditioned with 1 mL of methanol followed 
by 1 mL of water. The sample was then transferred to the SPE column and allowed to pass 
slowly through the HLB column. The column was washed with a 1 mL portion of 5% (v/v) 
solution of methanol in water. The column was then dried for 5 minutes with a flow of nitrogen. 
Elution of the derivatized samples was then performed with two 0.75 mL portions of 5% (v/v) 
acetic acid in acetonitrile. The eluate was dried at 50°C with a stream of nitrogen in a Turbovap 
evaporator. The dry residue was reconstituted with 100 µL of 25% (v/v) acetonitrile in water and 
vortexed, followed by 50 µL of water and vortexed. The tube contents were transferred to an 
22 
 
autosampler vial fitted with a glass insert. The injection volume was set to 20 µL. The mobile 
phases consisted of A: 0.1% formic acid in water and B: 0.1% formic acid in acetonitrile at a 
flow rate of 0.225 mL/min. The mobile phase began at 10% B with a linear gradient to 95% B in 
6 minutes, which was maintained for 1.5 minutes, followed by re-equilibration to 10% B. 
Separation was achieved with a Titan C18 column, 100 mm x 2.1 mm, 1.9 µm particles (Sigma 
Chemical Co., St. Louis, MO, USA) maintained at 45°C. DCA eluted at 3.3 minutes and the 
internal standard, d3-desfuroylceftiofuracetamide at 3.3 minutes. Full scan MS of the 
pseudomolecular ions of DCA (m/z 487) and the internal standard; d3-
desfuroylceftiofuracetamide (m/z 490) was used for analyte detection. The sum of the intensities 
of ions at m/z of 197, 241, 324, and 396 were used for DCA quantitation. The internal standard 
was quantitated with the sum of the ion intensities at m/z of 200, 244, 327, and 399. Sequences 
consisting of plasma blanks, calibration spikes, QC samples, and porcine plasma samples were 
batch processed with a processing method developed in the Xcalibur software (Thermo 
Scientific, San Jose, CA, USA). The processing method automatically identified and integrated 
each peak in each sample and calculated the calibration curve based on a weighted (1/X) 
quadratic fit. Plasma concentrations of ceftiofur in unknown samples were calculated by the 
Xcalibur software based on the calibration curve. 
Thirteen calibration spikes were prepared in porcine plasma covering the concentration 
range of 1 to 10,000 ng/mL. QC samples were prepared at concentrations of 15, 150, and 1500 
ng/mL and had been stored at -80°C for 12 months. Results were then viewed in the Quan 
Browser portion of the Xcalibur software. Calibration curves exhibited a correlation coefficient 
(r2) exceeding 0.999 across the entire concentration range with almost all of the calibrators 
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differing from their nominal value by less than 5%. QC samples at were within 2 to 8 % of their 
nominal values. 
Pharmacokinetic modeling and statistical analysis 
Plasma drug concentrations at respective time points were used to construct a time versus 
concentration curve for each pig. Noncompartmental pharmacokinetic (PK) analysis was applied 
to calculate the following clinically relevant parameters: area under curve time 0 to last time 
point (AUC0-,last), area under curve time 0 extrapolated to infinity (AUC0-∞), maximum 
concentration (Cmax), time to maximum concentration (Tmax), terminal half-life (T½λ), terminal 
slope (λz), clearance per fraction of dose absorbed (Cl/F), volume of distribution per fraction of 
dose absorbed (Vz/F). PK modeling was conducted using WinNonlin® software (WinNonlin 5.2, 
Pharsight Corporation, Mountain View, CA). 
Mixed model analysis of variance (ANOVA) was performed on PK parameters. 
Treatment was the fixed effect. The PK parameter of interest was the response variable. All PK 
parameters were treated as continuous, except Tmax was treated as a class variable. Pairwise 
comparison of PK parameter and differences due to treatment were determined using Tukey’s 
honest significant difference test (Tukey’s HSD). Statistical significance was set a priori at 
values of p ≤ 0.05. Statistical analysis was conducted using SAS software (version 9.4, SAS 
Institute, Cary, NC).  
Results 
Routine diagnostics  
Prior to allotment, all pigs were naïve for PRRSv. Control pigs remained PRRSv naïve 
throughout the study. All pigs had evidence of the infection or vaccination that was expected for 
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their respective group and there was no evidence of cross-contamination among groups. Routine 
diagnostic and viral characterization results are summarized in Table 3. 
Pharmacokinetics 
Concentration versus time curves for mean plasma concentrations of 
desfuroylceftiofuracetamide (DCA) in the Control group, Vx group, Challenge group, and 
Vx+Challenge group are displayed in Figure 1. Means and ranges of evaluated PK parameters 
with pairwise comparisons are summarized in Table 4. Control group, Vx group, and 
Vx+Challenge group had no significant difference on any evaluated PK parameter.  
The area under the curve of desfuroylceftiofuracetamide time zero to last time point is 
significantly lower in the Challenge group when compared to the other three groups. When 
considering AUC0-∞ the Challenge only group is significantly lower than the Vx group and the 
Vx+Challenge group, but the Challenge and Control groups are not significantly different. 
Percent extrapolated for AUC0-∞ is less than 4% for each group. 
Clearance per fraction of dose absorbed (Cl/F) and volume of distribution per fraction 
dose absorbed (Vz/F) are significantly higher in the Challenge group when compare to any of the 
other three groups other three groups.  The Vx+Challenge group had a significantly higher 
terminal slope (λz) than the Challenge group. Cmax was not significantly different among any 
group. There is a numerical appreciation of the Vx+ Challenge group having a higher Cmax than 
the Challenge group (Tukey’s p=0.0995). Tmax was significantly later in the Vx group when 
compared to the Challenge group. 
Discussion 
The first objective was to determine if vaccination with PRRS MLV impacted 
pharmacokinetics of CCFA. This study demonstrated that PRRS MLV does not impact the 
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pharmacokinetic parameters of CCFA compared to control animals that are not vaccinated or 
challenged. The second objective was to determine if PRRS MLV vaccination preserved 
pharmacokinetics of CCFA in the face of PRRSv challenge. This study determined vaccination 
with PRRS MLV preserved pharmacokinetic parameters in face of a wild type challenge.  
Comparing control animals to those receiving only the PRRS MLV, no differences were 
observed. Previous work has demonstrated the PRRS MLV (Ingelvac MLV®) used is for study 
will cause virema starting around three days after inoculation with peak virema occurring seven 
to fifteen days after inoculation (Johnson et al., 2004). The present work targeted peak virema of 
PRRS MLV by having a PK assessment of 240 hours duration, which commenced five days after 
vaccination (Vx group). Viremia was confirmed in the respective group by having all animals 
test PRRSv positive by routine PCR five after inoculation. Likewise, PRRS MLV in vivo 
replication in lung or tonsil tissue was demonstrated with the PRRS MLV specific RT-PCR used 
on tissues collected at necropsy. Despite viremia and in vivo replication with the PRRS MLV, 
when compared to control animals, there were no differences in the evaluated pharmacokinetic 
parameters of CCFA.  
Comparing control animals to those receiving a PRRSv wild-type challenge, CCFA in 
challenged animals had a higher Cl/F, higher Vz/F, and lower AUC0-last. The PK assessment had 
a duration of 240 hours, which commenced five days after challenging the animals (Challenge 
group). This timing targeted peak virema of the wild type virus, VR-2385, based on previous 
literature (Johnson et al., 2004).  Tantituvanont et al. (2008) found similar results with PRRSv 
challenged pigs and the pharmacokinetics of a shorter acting ceftiofur preparation, ceftiofur 
hydrochloride (HCl). Similar to observations in the present study with CCFA, ceftiofur HCl in 
PRRSv challenged pigs was reported to have a higher Cl/F, higher Vz/F and lower AUC. 
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Additionally, ceftiofur HCl in PRRSv infected animals was reported to have a lower Cmax, 
shorter mean residence time, shorter half-life, and an increased terminal slope.  
Comparing control animals to those vaccinated with the PRRS MLV prior to a PRRSv 
wild-type challenge, no differences were observed. Pigs had been vaccinated twenty-eight days 
before receiving a wild-type PRRSv challenge, and five days after challenge the pigs underwent 
the PK assessment for CCFA (Vx+Challenge group). This timing was aimed at achieving high 
levels of humoral and cellular immunity at time of challenge (Li et al., 2014). The timing also 
targeted peak viremia for the wild type virus at PK assessment (Johnson et al., 2004).  At time of 
challenge, all animals of the respective group were positive for antibody by ELISA. Protective 
nature of the measured antibody was not determined. However, presence of antibody 
demonstrated that all pigs of the respective group had an immune response after vaccination. 
Furthermore, all animals of the respective group had wild-type PRRSv infection in lung or tonsil 
tissue demonstrated with the PRRSv VR-2385 specific RT-PCR used on tissues collected at 
necropsy, so the effect was not a consequence of preventing wild-type infection with vaccine. 
Despite the challenge and infection with the wild-type PRRSv, pigs that had been previously 
vaccinated had no differences detected in the evaluated pharmacokinetic parameters of CCFA 
when compared to control animals.  
Other work has shown disease challenge in swine changes the pharmacokinetics of  
intravenous (IV) enrofloxacin, IV trimethoprim sulfadimethoxine, IV trimethoprim 
sulfamethoxazole, oral oxytetracycline, IV oxytetracycline, IM penicillin G, IV ampicillin, IV 
sulfadimidine, IV danofloxacin, intramuscular (IM) amoxicillin, and oral amoxicillin (Post et al., 
2002; Post et al., 2003; Mengelers et al., 1995; Pijpers et al., 1991; Pijpers et al., 1990; Zeng and 
Fung, 1990, Yuan et al., 1997; Lindecrona et al., 2000; Agerso et al., 2000; Jensen et al., 2004; ). 
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However, there is evidence that disease does not always change the pharmacokinetics of IV 
florfenicol, IM florfenicol, oral florfenicol, IV sulfadimethoxine, IV sulfamethoxazole, and IM 
ampicillin (Liu et al., 2003; Mengelers et al., 1995; Yuan et al., 1997).  Studies observing 
changes in pharmacokinetics shared a common theme of changes in volume of distribution, 
clearance, or both. The pharmacokinetic changes seen in the present study are suspected to be 
from a combination of impacts on volume of distribution, clearance, and absorption (F, fraction 
of dose absorbed, bioavailability from injection site). For absorption to be determined, an IV 
pharmacokinetic model must be established and referenced for comparison. In this study 
absorption could not be determined, because there were not duplicate treatment groups receiving 
an IV dose of CCFA. Absorption rate and extent of CCFA from the IM injection site remains 
unknown. With non-intravenous pharmacokinetics, the volume of distribution and clearance 
remain dependent upon absorption. There is reason to believe that a PRRSv infection could 
impact absorption, volume of distribution, and clearance. Others have suggested that disease may 
influence volume of distribution and clearance by altering capillary permeability, hepatic 
function, renal function, and plasma proteins available for drug binding (Riviere, 2009; 
Tantituvanont et al. 2008).  It also seems reasonable that an infection could change typical 
physiologic pH of the vasculature, which could potentially influence both absorption and protein 
binding. 
The present work found no differences in Cmax among any groups, and T½λ was higher in 
the pigs only receiving the wild-type PRRSv challenge when compared to pigs vaccinated prior 
to wild-type PRRSv challenge. It is well accepted that time above bacterial minimum inhibitory 
concentration (MIC) is a desired way to estimate effectiveness of β-lactam antibiotics (Papich, 
2014). Considering the Cmax and T½λ of the present work, it would be intuitive to suggest that 
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CCFA efficacy does not change in PRRSv challenged pigs regardless of vaccination status. 
However, a close examination of the concentration versus time curve should not be dismissed 
(Figure1). Consider the time each groups falls below 2µg/mL. The curve shows pigs receiving 
only the wild-type challenge fall below 2µg/mL approximately 24hours before any of the other 
groups. The Clinical and Laboratory Standards Institute (CLSI) has an established ceftiofur 
breakpoint, recognizing ceftiofur susceptibility at an MIC ≤2µg/mL for four organisms involved 
with swine respiratory disease, Actinobacillus pleuropneumoniae, Pasteurella multocida, 
Salmonella choleraesuis, and Streptococcus suis (CLSI, 2013).  It is acknowledged that the 
breakpoint is based on the parent compound of ceftiofur, the main metabolite in pigs is 
desfurolyceftiofur, and the compound evaluated in the present study is a stable derivative 
representing ceftiofur metabolites. It is also acknowledged that using breakpoint criteria and a 
concentration versus time curve cannot be directly correlated with antimicrobial efficacy. 
However, present observations would suggest  PRRS MLV vaccination has the potential to 
preserve time-dependent CCFA efficacy in pigs faced with PRRSv wild-type challenge. 
Observations of the present study suggest that PRRS MLV does not change the 
pharmacokinetics of CCFA, PRRSv wild-type infection does change the pharmacokinetics of 
CCFA, and previous vaccination has the potential to preserve the pharmacokinetics of CCFA in 
face of a wild-type PRRSv challenge. The present study did not evaluate antimicrobial or 
vaccine efficacy. Future work could focus on understanding possible bioavailability changes. 
Additionally, measurements of vascular pH and plasma proteins could possible help suggest 
reasons for observed changes.  
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CHAPTER 4 
POLYMERASE CHAIN REACTION TEST DEVELOPMENT AND APPLICATION FOR 
VIRAL DETECTION, SEQUENCING AND QUALITY CONTROL IN A STUDY 
DETERMINING VACCINATION MITIGATES THE IMPACT PRRSV INFECTION HAS ON 
THE PHARMACOKINETICS OF CEFTIOFUR CRYSTALLINE FREE ACID IN PIGS 
 
 
Introduction 
The original research outlined in Chapter 3 used PRRS MLV vaccination and PRRSv 
VR-2385 wild-type challenge. Meaningful pharmacokinetic results were contingent on high 
confidence in the vaccination or wild-type infection status of the groups.  Routine PRRSv PCR 
assays are unable to differentiate viral strains. The development of a strain-specific PRRSv RT-
PCR, was needed to check and confirm the status of the study groups. This strain-specific 
PRRSv RT-PCR was able to individually differentiate and quantify PRRS MLV strain and 
PRRSv VR-2385 wild-type strain. In development and execution of strain specific RT-PCR, 
viral sequencing was performed on samples. Sequencing was performed as a means to gain 
better understand the genetic behavior of the virus in live animals. Sequencing also served as 
quality assurance for the RT-PCR. 
In addition to sequencing, lung histopathology and PRRSv immunohistochemistry (IHC) 
on lung and tonsil tissue were performed as part of the research outlined in Chapter 3. In effort to 
remain concise for publication, this information was not included in the journal submission 
describing PK changes. This chapter includes the information regarding PRRSv sequencing, 
histopathology scoring of lung tissue, and PRRSv IHC on lung and tonsil tissue. 
PRRSv Sequencing 
 
 Sequencing was performed on select lung and tonsil samples to confirm validity of the 
strain specific PCRs. Sequence data were assembled and analyzed using the DNAStar Lasergene 
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11 Core Suite. Aliquots of the specific VR-2385 inoculum and Ingelvac® MLV vaccine were 
used for quality assurance of the strain specific RT-PRCs and sequence referencing. All lung 
samples from the Control Group tested negative for PRRSV by all strain specific RT-PCRs.  
For the Vx Goup, 8 out of 10 lung samples tested positive by MLV-specific ORF5 and 
nsp2 RT-PCRs. The PCR products were attempted for sequencing. The ORF5 PCR products 
from 8 lung samples were successfully sequenced and confirmed as Ingelvac® MLV. Attempts to 
sequence the nsp2 region of MLV virus detected in two lung samples were unsuccessful. 
However, the nsp2 region of MLV virus detected in the other six lung samples was successfully 
sequenced and confirmed as Ingelvac® MLV. For the two lung samples that were negative by 
MLV-specific ORF5 and nsp2 RT-PCRs, tonsils from the two pigs were tested by these MLV-
specific RT-PCRs. The tonsils samples were positive by MLV-specific ORF5 and nsp2 RT-
PCRs. The ORF5 and nsp2 regions of virus detected in one tonsil sample were successfully 
sequenced and confirmed as Ingelvac® MLV. But attempts to sequence the other tonsil sample 
were unsuccessful. None of the 10 lungs samples and 2 tonsil samples were positive by VR2385-
specific ORF5 or nsp2 RT-PCRs.  
For the Challenge Group, 10 out of 10 lung samples were positive by VR-2385-specific 
ORF5 and nsp2 RT-PCRs. The PCR products were successfully sequenced and confirmed as 
VR-2385 virus, except the nsp2 region of virus detected in one lung was unsuccessful in 
sequencing. All of the 10 lung samples were negative by MLV-specific ORF5 and nsp2 PCRs. 
For the Vx+Challenge Group, only one lung sample was positive for both MLV and VR-
2385 concurrently. Seven lung samples were positive for VR-2385 but negative for MLV. 
Sequencing confirmed the identities of PCR products. Two lung samples were negative for both 
VR-2385 and MLV. In order to determine if tonsils from this group of pigs contained both VR-
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2385 and MLV, the 10 tonsil samples were tested by MLV-specific ORF5 and nsp2 RT-PCRs 
and VR-2385-specific ORF5 and nsp2 RT-PCRs. All of the 10 tonsils were positive for both 
Ingelvac® MLV and VR2-385 viruses and confirmed by sequencing. 
 The MLV viruses recovered from Vx and Vx+ Challenge groups shared 99.1-100% ORF5 
nucleotide identities to each other and to the Ingelvac® MLV vaccine virus that was used to 
vaccinate pigs. Point mutations were observed at five positions of ORF5 and no insertions or 
deletions were observed. The MLV viruses recovered from the Vx and Vx+Challenge groups 
shared 99.2-100% nsp2 nucleotide identities to each other and 99.8-100% nsp2 nucleotide 
identities to the Ingelvac® MLV vaccine virus that was used to vaccinate pigs. Point mutations 
were observed at 5 positions of nsp2. Interestingly, a 9-nucleotide deletion 5’GTTCTGGGA3’ at 
nucleotide positions 3118-3126 was observed in nsp2 region of MLV viruses recovered from 
three pigs in the Vx groups and three pigs in the Vx+Challenge group. The biological 
significance of this 9-nucleotide deletion was not determined. 
The VR-2385 viruses recovered from Challenge and Vx+Challenge groups shared 99.8-
100% ORF5 nucleotide identities to each other and to the VR-2385 PRRSV that was used to 
challenge pigs. Point mutations were observed at 2 positions of ORF5 and no insertions or 
deletions were observed. The VR-2385 viruses recovered from Challenge and Vx+Challenge 
groups shared 99.2-100% nsp2 nucleotide sequences to each other and 99.6-100% nsp2 
nucleotide identities to the VR-2385 PRRSV that was used to challenge pigs. Point mutations 
were observed at six positions of nsp2 and no insertions or deletions were observed.  
Histopathology & PRRSv IHC  
 
 Lung and tonsil tissues were collected at necropsy and placed in 10% buffered neutral 
formalin. After 24 hours of formalin fixation, tissues were transferred to 70% isopropyl alcohol 
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until hematoxylin and eosin staining and slide preparation was performed. Histopathology 
included scoring for interstitial pneumonia. The scores of 0, 1, 2, 3, 4, 5, and 6, corresponded to 
normal lung, mild multifocal interstitial pneumonia, mild diffuse pneumonia, moderate 
multifocal pneumonia, moderate diffuse pneumonia, severe multifocal pneumonia, and severe 
diffuse pneumonia, respectively.  This interstitial pneumonia scoring system was based on 
previously established standards (Halbur et al., 1996).  PRRSv immunohistochemistry (IHC) was 
performed on the formalin and alcohol fixed lung tissue. If lung tissue did not stain IHC positive, 
tonsil was then tested.  
Statistical analysis was not performed on histopathology scoring or IHC data. Analysis 
was not performed, because the study design was not created to evaluate lung pathology. Sample 
size of treatment groups was constructed for pharmacokinetic evaluation, not lung pathology 
evaluation. The time lung samples were collected was not targeting peak virema. The use on an 
antibiotic could be a potential confounder. 
Histopathology scoring results are summarized in Table 5. Histopathology scores 
averaged 2.25, 1.6, 3.9, and 3.0 for the Control, Vx, Challenge, and Vx+Challenge groups, 
respectively. The two groups receiving the wild-type challenge did have scores appreciably 
higher. Interestingly, the lung scoring averaged slightly better, scored lower, in the Vx Group 
when compared to the Control Group.  There are several reasons why the average scores might 
not be exactly as expected. Scoring is subjective. Under the microscope, the person scoring is 
limited to make judgment on evaluation of very small portion of lung. Variation could occur in 
necropsy collection and sample preparation, as well.  
PRRSV IHC results are summarized in Table 5. There were no positive samples in the 
Control Group. There were 3/10, 8/10, and 5/10 positives in the Vx, Challenge, and 
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Vx+Challenge Groups, respectively. In the Vx Group, one of the three positives only stained 
positive on tonsil. In the Challenge Group, five of the eight positives only stained positive on 
tonsil. In the Vx+Challenge group, four of the five positives only stained positive on tonsil. 
PRRSV IHC is often used for analytical specificity and not sensitivity. For an IHC to be positive, 
viral antigen needs to be present in the small section of lung being evaluated under the 
microscope. That viral antigen must have an epitope able to be bound by antibody in the IHC 
assay. The specificity and sensitivity was demonstrated in these results. The Control Group had 
no positives, confirmed my RT-PCR. The other groups had only a proportion of the group 
positive for PRRSv by IHC. However, all pigs in these groups were RT-PCR positive. This study 
was not constructed to evaluate or demonstrate PRRSv IHC capabilities. The data were used to 
help understand PRRSv infection, in contrast to all other information. 
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CHAPTER 5 
SUMMARY AND CONCLUSIONS 
 
PRRSv influence briefly summarized 
The original work of this thesis demonstrated PRRSv infection changes the 
pharmacokinetics of CCFA. This is the first time this disease-antimicrobial interaction has been 
investigated. Furthermore, this original research investigated the potential impact of PRRS MLV 
vaccination. The vaccine did not change pharmacokinetics of CCFA, and when used as a 
vaccine, it could prevent PK changes seen in a PRRSv wild-type challenge. This is the first time 
a vaccine has been investigated with swine antimicrobial pharmacokinetics. There are three other 
swine studies that used PRRSv as an infection model (Day et al., 2015; Godoy et al., 2011; 
Tantituvanont et al., 2009). Two of the studies had a bacterial component (Day et al., 2015; 
Godoy et al., 2011). All three of the studies used a β-lactam antibiotics, and each study found 
disease changed pharmacokinetics.  
There are two salient features that make PRRSv infection and vaccination ideal for 
investigation. First, PRRSv related disease has substantial impact on the swine population 
(Holtkamp et al. 2013). Second, the use of a viral challenge model allows disease-influenced 
pharmacokinetic changes to be better attributed to physiological changes and not presence of an 
organism. In some pharmacokinetic studies the use of an organism may be considered a 
confounder, because of the potential consumption, metabolism, or other alteration of the 
antimicrobial by target bacteria. An example would be pharmacokinetic changes of penicillin G 
in S. suis challenged pigs (Zeng and Fung, 1990); some of the pharmacokinetic changes could be 
a result of antimicrobial consumption by the S. suis organism. In the pure sense, it would be best 
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to know the pharmacokinetic changes that are a result of the body’s physiologic change in a 
disease state. Viral and toxin challenge models avoid this potential confounder.  
It is biologically intriguing that pharmacokinetic differences were observed in PRRSv 
wild-type challenged pigs and not pigs receiving PRRS MLV. It is noteworthy that previous 
PRRS MLV vaccination prevented pharmacokinetic changes observed in face of a PRRSv wild-
type challenge. Ingelvac® PRRS MLV, used in the present research, has been available as a 
commercial vaccine since 1996, and it is simply an attenuated VR-2332 field virus that was 
passaged in monkey kidney cells (Kim et al., 2008). There is a vast amount of research 
evaluating PRRSv infection, and there is a decent body research that evaluates PRRS MLV. One 
study found significantly less severe lung lesions in pigs inoculated with PRRS MLV when 
compared to pigs inoculated with VR-2385, the challenge strain used in the present research of 
this thesis (Opriessnig, et al., 2002). However, they did find some lesions in the group only 
receiving PRRS MLV. Another study measured immune responses in pigs vaccinated with 
PRRS MLV prior to challenge with homologous or heterologous PRRSv (Li et al., 2014). They 
found PRRS MLV vaccination induced neutralizing antibodies with partial protection against 
heterologous challenge, but they found cytokine expressions and T-cell subpopulations did not 
differ between homologous or heterologous challenge. These two studies are examples of some 
observed behavior of the PRRS MLV, yet there is much unknown.  
There are several mechanisms by which PRRSv could be inhibiting a pig’s ability to 
normally absorb, distribute, metabolize, or excrete a drug. PRRSv has the potential to influence 
many of the previously mentioned pharmacokinetic changing mechanisms, renal function, 
protein binding, vascular function, and many others. PRRSv has potential to cause vasculitis and 
necrosis in kidneys (Cooper et al., 1997). Considering protein binding, there are numerous 
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studies on PRRSv evaluating cytokine expression and immune cells response, all which have the 
potential to change protein binding in the blood (Parra et al., 2006; Gómez-Laguna et al., 2010; 
Silva-Campa 2009; Wongyanin et al., 2010). The generalized infection and inflammation caused 
by PRRSv could cause changes in vascular permeability and blood flow (Halbur et al., 1995; 
Halbur et al., 1996; Rossow, 1998). With the disease caused in lungs and possible kidneys, it is 
also reasonable to consider that blood pH could be another mechanistic change. There are several 
other mechanisms that could conceivably contribute to changes seen. Vaccination with PRRS 
MLV could partially or fully prevent specific changes. 
In the present work of the thesis and with the bounds of the materials and methods, PRRS 
MLV vaccination does not appreciably change the way a pig’s body handles CCFA. PRRSv 
challenge does change the way a pig’s body handles CCFA. PRRS MLV vaccination prior to 
PRRSv challenge allows the pig’s body to handle CCFA as if it were not challenged. 
Future areas to investigate 
To attempt to understand reasons behind the observed pharmacokinetic changes, future 
research could be based from altered pharmacokinetic parameters observed with this present 
study, Cl, Vd, and F. The faction of dose absorbed (F, bioavailability) was not measured in the 
present study because of the lack of IV treatment groups. Obtaining IV pharmacokinetic data to 
establishing bioavailability knowledge would help understanding. Measuring blood pH might be 
a means to understand bioavailability and drug distribution. As mentioned earlier, compound 
ionization is often dependent on pH, and ionization influences the ability for a compound to 
cross biological membranes, which is why measuring blood pH may be insightful. Evaluating 
tissue concentrations could help understand distribution. Measuring protein binding could help 
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elucidate distribution and clearance. Evaluating renal function and elimination would be methods 
for understanding clearance.  
Clinical implications and final conclusions 
Pharmacokinetic data are used to establish dosing regimens for efficacious treatment. 
Within food animals, pharmacokinetic data are also important to establish drug withdrawal times 
to avoid antimicrobial residues in the human food supply. Disease has the potential to change 
pharmacokinetics and subsequently change antimicrobial efficacy or withdrawal times. The 
specific drug and disease seem to be relevant as to whether pharmacokinetic changes will truly 
occur. However, the available information for swine suggests a majority of the time disease will 
change the pharmacokinetics of a given drug. When faced with using an antibiotic in clinical 
practice, a literature search should first be completed attempting to find if research has been done 
with the specific disease and antibiotic of interest. If there is not a match, utilization of the best 
available data should be implemented. After drug use, a case should be followed to note 
treatment success and failure. The information from research and diligent experience is what 
should be utilized to go forward with practicing antimicrobial usage. In clinical food animal 
practice, anytime a drug is being administered, the question should be asked, “Is this drug being 
given at the correct dose and route in order to reach the target site in the animal at a level that 
will be efficacious, yet not toxic or in residue violation?”
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Figure 1. Plasma concentration versus time curves for mean plasma concentrations of 
desfuroylceftiofuracetamide. 
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NSD = No Significant Difference, ↑= PK parameter increased, ↓= PK parameter decreased, ---- = PK parameter not evaluated,  
POg = per os by gavage, POa = per os by ad libitum 
† In combination with 25 mg SDM/kg  BW  ‡ In combination with 25 mg SMX/kg  BW 
*Natural infection with the primary agent being PRRSV, and P. multocida, B. bronchiseptica, and S. suis as opportunistic pathogens. 
§Disease challenged performed with toxin or LPS, not actual organism. 
#Study did not statistically report
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Table 1. Summary of studies evaluating disease influence on antimicrobial pharmacokinetics is swine (adapted from Day, 2014) 
Disease  Drug Evaluated  PK Parameters Evaluated (Increase, Decrease) 
Citation 
Agent Drug Route Dose (mg/kg) AUC CMAX MRT TMAX T1/2 Vz CL Elimination 
APP 
Florfenicol IV 20 NSD NSD NSD NSD NSD VSS NSD Cl NSD ----- ----- Liu, 2003 
Florfenicol IM 20 NSD NSD NSD NSD NSD VSS NSD Cl/F NSD ----- ----- Liu, 2003 
Florfenicol POg 20 NSD NSD NSD NSD NSD VSS NSD Cl/F NSD ----- ----- Liu, 2003 
Enrofloxacin IV 5 NSD ----- ----- ----- ↓ VSS ↑ Cltot NSD β ↑ Post, 2002 
Enro + dexamethasone IV 5, 0.5 ↓ ----- ----- ----- ↓ VSS NSD Cltot ↑ β ↑ Post, 2002 
Amoxicillin IV 8.6 NSD ----- NSD ----- NSD Vss NSD Cltot NSD ----- ----- Agerso, 1998 
Sulfadimethoxine§ IV 25 NSD ----- ----- ----- NSD Vd NSD Cltot NSD ----- ----- Mengelers, 1995 
Sulfamethoxazole§ IV 25 NSD ----- ----- ----- NSD Vd NSD Cltot NSD ----- ----- Mengelers, 1995 
Trimethoprim†,§ IV 5 ↓ ----- ----- ----- NSD Vd ↑ Cltot ↑ ----- ----- Mengelers, 1995 
Trimethoprim‡,§ IV 5 ↓ ----- ----- ----- NSD Vd ↑ Cltot ↑ ----- ----- Mengelers, 1995 
Oxytetracycline§ POg 50 ↑ ↓ ----- ↑ NSD Vd ↑ Cltot ↓ β ↓ Pijpers, 1991 
Oxytetracycline§ IV 10 ↑ ----- ----- ----- ↓ Vdβ ↓ Cltot ↓ β ↑ Pijpers, 1990 
Oxytetracycline§ IV 50 NSD ----- ----- ----- NSD Vdβ NSD Cltot NSD β ↑ Pijpers, 1990 
PRRSV 
Ceftiofur hydrochloride IM 3 ↓ ↓ ↓ NSD ↓ Vz/F ↑ CL/F ↑ λz ↑ Tantituvanont, 2009 
Amoxicillin* POa 9 ↑ ↑ NSD ----- ----- ----- ----- Clp NSD ----- ----- Godoy et al., 2011 
PRRSV + 
Strep suis Ceftiofur hydrochloride IM 5 ↓ ↓ NSD NSD NSD Vz/F ↑ CL/F ↑ Kel NSD Day et al., 2015 
Strep suis Penicillin G IM 15,000 iu ↓ ↓ ----- NSD NSD Vd ↑ Clb ↑ Kel NSD Zeng & Fung, 1990 
Strep suum 
Ampicillin IV 10 ↓ ----- ----- ----- NSD Vss ↑ Clb ↑ K10 ↑ Yuan, 1997 
Ampicillin IM 10 NSD ----- ----- ----- NSD Vss NSD Clb NSD ----- ----- Yuan, 1997 
Sulfadimidine IV 50 ↑ ----- ----- ----- ↑ Vss NSD Clb ↓ K10 NSD Yuan, 1997 
Salmonella 
typhimurium 
Danofloxacin IV 2.4 ↑ ----- ----- ----- ↑ Vss ↓ Clb ↓ ----- ----- Lindecrona, 2000 
Amoxicillin IM 15 NSD NSD ↑ NSD ↑ V/F ↑ ----- ----- Kel ↓ Agerso, 2000 
E. coli 
Amoxicillin POa 26-32 ↓ ↓ ----- ↑ ↑ ----- ----- ----- ----- Kel ↓ Jensen, 2006 
Amoxicillin POg 20 ↓ ↓ ----- NSD NSD ----- ----- ----- ----- Kel NSD Jensen, 2004 
Enrofloxacin IV 5 ↑ ----- ----- ----- ↑ Vβ NSD Clb ↓ β ↓ Post, 2003 
Enro + dexamethasone§ IV 5, 0.5 NSD ----- ----- ----- NSD Vβ ↑ Clb NSD β NSD Post, 2003 
Antipyrine§ POg 150 ----- ----- ----- ----- ↑ Vd ↑ Cltot ----- Kel ↓ Ladefoged, 1979# 
Trimethoprim§ POg 20 ----- ----- ----- ----- ↑ Vd ↑ Cltot ----- Kel ↓ Ladefoged, 1979# 
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Table 2. Summary of study design events. 
   Event and study day 
Group  
(code) 
No. of 
pigs  
Vaccination with 
Ingelvac® PRRS MLV 
Challenge with 
PRRSv VR-2385 
PK 
Assessment Necropsy 
Control  
(Control) 8  None None Days 0 to 9 Day 9 
PRRS MLV 
 (Vx) 10  Day -5 None Days 0 to 9 Day 9 
PRRSv Challenge 
(Challenge) 10  None  Day -5 Days 0 to 9 Day 9 
PRRS MLV vaccination 
followed by Challenge 
(Vx+Challenge) 
10  Day -33 Day -5 Days 0 to 9 Day 9 
 
 
 
 
 
 
 
 
 
Table 3. Summary of PRRSv routine diagnostics and viral characterization 
Group  
Study Day, test type, and frequency of positives 
Prior to allotment  -5  0  9 
Routine 
PCR ELISA  ELISA  
Routine 
PCR  
Routine 
PCR 
MLV  
specific PCRs 
VR-2385 
specific PCRs 
Control  
0/38 0/38  
NP  0/8  0/8 0/8 0/8 
Vx  NP  10/10  9/10 10/10 0/10 
Challenge  NP  10/10  10/10 0/10 10/10 
Vx+ Challenge  10/10  9/10  8/10 10/10 10/10 
Routine PRCs and antibody ELISAs were run on serum. MLV and VR-2385 specific PCRs were run on lung or tonsil.  
NP, not performed  
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Table 4. Plasma pharmacokinetic parameters (arithmetic mean and range) of ceftiofur and 
related metabolites amongst treatment groups. Values in a row with identical superscripts 
are not significantly different (Tukey’s HSD, P < 0.05). 
      
Parameter Units Control Vx Challenge Vx+Challenge 
AUC % 
extrapolated 
% 2.20 
(0.85-4.72)a,b 
2.19 
(0.76-4.45)a,b 
3.87 
(1.45-10.5)a 
1.41 
(0.32-2.70)b 
AUC0-∞ h*µg/mL 334 (281-400)a, b 
345 
 (303-415)a 
281 
(194-332)b 
344 
(286-418)a 
AUC0-last h*µg/mL 327 (277-390)a 
338 
(297-411)a 
270 
 (185-321)b 
 339 
 (281-410)a 
Cl/F mL/h/kg 15.2 
(12.5-17.8)a 
14.6 
(12.1-16.5)a 
18.2 
(15.1-25.8)b 
14.8 
(12.0-17.5)a 
Cmax µg/mL 4.30 
(3.24-5.42)a 
3.91 
(2.82-6.13)a 
3.68 
 (2.61-4.89)a 
4.55 
 (3.52-5.61)a 
T1/2λ h 41.7 
(33.4-55.3)a,b 
42.4 
(29.9-53.0)a,b 
50.9 
(39.6-95.2)a 
38.0 
(29.4-43.9)b 
λz 1/h 0.01692 
(0.01-0.02) a,b 
0.01695 
(0.01-0.02) a,b 
0.01459 
(0.01-0.02) a 
0.01859 
(0.02-0.02) b 
Tmax h 14.3 
(6.00-24.0) a,b 
24.0 
(12.0-48.0)a 
11.4 
(6.00-24.0)b 
19.8 
(6.00-24.0) a,b 
Vz/F mL/kg 915 
(689-1310)a 
899 
(604-1130)a 
1330 
(987-2140)b 
804 
(602-965)a 
  
    
 
Table 5. Summary of histopathology and PRRSv IHC 
Group 
 
n 
 
Histopathology: average lung 
score (range) 
PRRSv IHC  
(proportion of positive animals, 
lung or tonsil) 
Control  8  2.25 (1-5)  0/8 
Vx  10  1.6 (0-3)  3/10 
Challenge  10  3.9 (1-6)  8/10 
Vx+Challenge  10  3.0 (1-5)  5/10 
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